Hologic's Mixed Performance: A Deep Dive

Hologic, a key player in womens health, has seen its stock reach a 52-week high of $76.29 in December, currently trading slightly below. Over the past three months, it has outperformed the Nasdaq Composite with a 12.7% increase. Despite mixed performance over the past year, Hologics stock has mostly stayed above key moving averages since late May and early August. The companys Q3 results, released in November, showed a 6.2% year-over-year revenue growth, beating expectations, driven by US and international revenue increases. Operating margins improved, and non-GAAP earnings per share surged by nearly 12%, also beating estimates. Analysts have a Hold rating on Hologic stock with a modest 2.8% upside potential.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.